India's Shilpa Medicare jumps on completing clinical trial of albumin drug
07/08/2024 08:08
** Shares of Shilpa Medicare SHME.NS rose as much as 8.1%,
to 719.64 rupees, last up 7.2%
** Shilpa Medicare completes phase 1 clinical trial for
Recombinant Human Albumin (rHA) 20%
** Albumin is used in medical treatments, including
restoring blood volume, replacing lost fluids, and serious burn
injuries
** Stock up ~115% YTD
(Reporting by Yagnoseni Das in Bengaluru)
((Yagnoseni.das@thomsonreuters.com))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026